A Biosimilar Shot In The Arm
Forbes India|December 28, 2018 (Rich List)

Kiran Mazumdar-Shaw’s successful foray into the lucrative US biosimilars market has resulted in a surge in her ranking among India’s rich

Harichandan Arakali
A Biosimilar Shot In The Arm

In June, when Biocon and its commercial partner Mylan NV announced they had won the USFDA approval for their bio-generic version of the drug Pegfilgrastim, it was the second approval Biocon was getting in America for a ‘biosimilar’ it had developed for use in certain cancer-related treatments. The company is marketing its Pegfilgrastim biosimilar under the brand name Fulphila.

Earlier this year, the Bengaluru company built by billionaire Kiran Mazumdar-Shaw had announced a global teamup with Sandoz, a unit of pharmaceuticals company Novartis AG, to develop and commercialise biosimilars. This was shortly after Biocon became the first company in the world to win US FDA approval for its version of Trastuzumab, which it would market under the name Ogivry.

Partnerships such as the ones with Mylan and Sandoz show that Biocon has won the respect of some of the largest players in the multinational pharmaceuticals business. That is reflected in the surge in Shaw’s ranking this year, among India’s richest.

The last 12 months have seen Shaw’s vision of building a deep R&D-based biotech firm, and not just a copycat chemical generics maker, vindicated. Investors took notice, too, pushing up the company’s stock to levels where Shaw’s personal wealth rose by some two-thirds to $3.6 billion. That made Shaw the biggest gainer in percentage terms in this year’s list of billionaires in India—her rank jumped from 72 last year to 39.

This story is from the December 28, 2018 (Rich List) edition of Forbes India.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the December 28, 2018 (Rich List) edition of Forbes India.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM FORBES INDIAView All
Home-Cooked Meal Is Now Greatly Valued
Forbes India

Home-Cooked Meal Is Now Greatly Valued

The pandemic has also brought with it an improved focus on hygiene, use of technology in dining, rise of cloud kitchens and resurgence in popularity of Indian ingredients

time-read
8 mins  |
May 21, 2021
Paytm 3.0 - Reaching Near Breakeven In Two Years
Forbes India

Paytm 3.0 - Reaching Near Breakeven In Two Years

As of 2020, Vijay Shekhar Sharma’s super app for financial services had run up losses in thousands of crores. Now, as digital payments gets yet another boost courtesy Covid-19, he’s hopeful of reaching near breakeven in two years

time-read
10+ mins  |
June 4, 2021
THE PANDEMIC HAS CAUSED WOMEN GREATER LABOUR PAIN
Forbes India

THE PANDEMIC HAS CAUSED WOMEN GREATER LABOUR PAIN

Covid-19 has shown that women are more likely to face the brunt of job losses than men, and find fewer opportunities when they want to resume. That apart, several have to deal with increased hours of unpaid work at home and even domestic abuse

time-read
8 mins  |
May 21, 2021
LEADERSHIP WILL BE ABOUT SEEING THE BIGGER PICTURE
Forbes India

LEADERSHIP WILL BE ABOUT SEEING THE BIGGER PICTURE

Leaders must not only guard their teams first during a crisis, but also deal with stakeholders with respect and dignity. And apart from pursuing business goals, they should remain committed to our planet and the environment

time-read
7 mins  |
May 21, 2021
PHILANTHROPY SHOULD BE HUMBLE, BUT NOT MODEST
Forbes India

PHILANTHROPY SHOULD BE HUMBLE, BUT NOT MODEST

Apart from building a flexible and resilient framework for the future, philanthropists, civil society and the government must work in tandem so that every rupee is absorbed on the ground

time-read
9 mins  |
May 21, 2021
INTEGRATED HEALTH CARE, TECH WILL DISRUPT SECTOR
Forbes India

INTEGRATED HEALTH CARE, TECH WILL DISRUPT SECTOR

While clinical research will get a boost, having a skilled workforce and public spending on health care will be challenges in the near term

time-read
8 mins  |
May 21, 2021
DIGITALISATION WILL HELP IN VALUE CREATION
Forbes India

DIGITALISATION WILL HELP IN VALUE CREATION

As the pandemic brings technology and innovation to the core of business and daily life, the next decade will see about 150 million digital-first families in India

time-read
8 mins  |
May 21, 2021
Industry 4.0: Climate Revolution?
Forbes India

Industry 4.0: Climate Revolution?

Augmenting sustainability alongside digital capabilities is an economic, competitive and global opportunity for India’s businesses, but regulations need to reflect intent

time-read
10 mins  |
June 4, 2021
EV Dream Still Miles Away
Forbes India

EV Dream Still Miles Away

Electric vehicles have remained a buzzword in India for years. But not much has moved on ground due to high upfront costs, range anxiety and charging infrastructure

time-read
6 mins  |
June 4, 2021
Living Waters
Forbes India

Living Waters

A virus has caused us to scramble for oxygen but our chokehold on the environment is slowly strangling the very waters that breathe life into us. The virus is a timely reminder: We are merely consumers, not producers of life’s breath on this planet

time-read
4 mins  |
June 4, 2021